Report : Middle East & Africa Blood Plasma Derivatives Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand’s Diseases, and Others), and End User (Hospitals, Clinics, and Others)

At 8.0% CAGR, the Middle East & Africa Blood Plasma Derivatives Market is speculated to be worth US$ 2,223.69 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa blood plasma derivatives market was valued at US$ 1,402.51 million in 2022 and is expected to reach US$ 2,223.69 million by 2028, registering a CAGR of 8.0% from 2022 to 2028. Increase in prevalence of blood disorders and rise in geriatric population are the critical factors attributed to the Middle East & Africa blood plasma derivatives market expansion.

Immunoglobulin G (IgG) therapies are highly used to treat primary immune deficiency cause by the genetics. The demand for IgG has been increasing steadily for the last few years due to the increasing awareness of IgG therapy. The growth is also accounted for its new therapy for its newly identified indication. Based on controlled trials done by Network Meta Analysis (NMA), IgG therapy has been approved for the treatment of Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and dermatomyositis. The Immunoglobulin G (IgG) therapies is also effective for the treatment of myasthenia gravis exacerbations and stiff-person syndrome. In addition, it provides convincing efficacy in autoimmune disorders like epilepsy, neuromyelitis, and autoimmune encephalitis.

A large proportion of IgG is used in specialties outside of immunology, such as oncology, neurology, hematology, and rheumatology. Compared to all, neurology is the fastest-growing specialty in the global market. The growth of the Immunoglobulin G market is attributed due to its approved for on-label use for chronic inflammatory demyelinating polyneuropathy (CIDP) followed by its off-label use in secondary immune deficiencies caused by lymphoma, myeloma, and leukemia and the certain immunosuppressive therapies esp. B-cell targeting therapies. Thus the wide range of IgG usage in multiple treatments for on-label and off-label prescription will continue to expand and drive IgG demand across the global market in the coming years.

On the contrary, complicated reimbursement policies hurdles the growth of Middle East & Africa blood plasma derivatives market.

The Middle East & Africa blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held 44.3% market share in 2022, amassing US$ 618.75 million. It is projected to garner US$ 1,006.67 million by 2028 to expand at 8.4% CAGR during 2022–2028.

Based on application, the Middle East & Africa blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held 33.4% market share in 2022, amassing US$ 465.90 million. It is projected to garner US$ 765.13 million by 2028 to expand at 8.6% CAGR during 2022–2028.

The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held 60.2% market share in 2022, amassing US$ 845.94 million. It is projected to garner US$ 1,328.38 million by 2028 to expand at 7.8% CAGR during 2022–2028.

Based on country, the Middle East & Africa blood plasma derivatives market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 44.2% market share in 2022. It was assessed at US$ 620.50 million in 2022 and is likely to hit US$ 973.55 million by 2028, exhibiting a CAGR of 7.8% during the forecast period.

Key players dominating the Middle East & Africa blood plasma derivatives market are Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; CSL Behring LLC; LFB SA; Kedrion SpA; and Fusion Health Care Pvt Ltd, among others. 

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

Download Free PDF Brochure